Business

This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month

MarketWatch · September 22, 2026 at 11:46 AM

This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month

Viking Therapeutics is developing VK2735, a GLP-1/GIP drug that could compete with Eli Lilly’s Zepbound.

Its stock is soaring.

5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.marketwatch.com — the content belongs to MarketWatch.

This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month

More from MarketWatch

S&P 500 at 10,000 or bust: New ETF offers investors all-or-nothing bet on the index

‘I have no children’: My aunt gave me $50,000 for a down payment. Now she wants me to leave my home to her two children.

‘I feel like a loser’: My stock portfolio is swinging wildly. Should I be worried?

My brother-in-law convinced his parents to sign over their home and life savings to buy a $3 million compound. Do I intervene?

More in Business

The Iran war is exposing dangerous gaps in the US military system built to save wounded troops

I used to feel embarrassed about graduating from a trade school. But now my career is safe from AI.

Nvidia GPUs are everywhere. Here are the ways companies are accessing them

S&P 500 at 10,000 or bust: New ETF offers investors all-or-nothing bet on the index

‘I have no children’: My aunt gave me $50,000 for a down payment. Now she wants me to leave my home to her two children.

As companies pour billions into Earth-based AI infrastructure, Google is taking the data center race off-planet